Muireann Bolger

Key details

Muireann Bolger is deputy editor of World Intellectual Property Review and Life Sciences Intellectual Property Review in London, where she covers trademarks, brands, as well as wider developments across the intellectual property sector.

She regularly attends and covers major IP conferences around the world, reporting on the latest legal, commercial and policy developments and interviewing leading figures from across the sector. She has also co-authored industry reports with leading IP organisations, including the International Trademark Association (INTA).

She is the editor of the website’s Community & Inclusion channel and the annual Influential Women in IP list, which celebrates the achievements and contributions of leading women across the IP sector.

Originally from Ireland, Muireann has nearly two decades of experience reporting on brand developments, strategy, and wider business issues.

In her current role, she writes and edits news and analysis for an international audience of IP professionals, while also championing inclusion within the profession.

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Total results: 415

Articles by Muireann Bolger

Sandoz eyes US biosimilar launch as Regeneron settles
Americas
Deal resolves just one case in Regeneron’s roll-call of actions against competitors looking to launch versions of a $6bn-a-year blockbuster eye-disease treatment.   11 September 2025
UK gets new IP minister following cabinet reshuffle
Careers
Wales’ first MP of ethnic minority background brings tech knowledge and expertise to the IP office, which is carrying out two pivotal consultations.   9 September 2025
Former PTAB judge joins Sterne Kessler
Careers
Appointment is the third ex-PTAB staffer to join, strengthens the firm’s position as a “PTAB powerhouse”.   8 September 2025
Careers
A litigator, who led the Unified Patent Court group at his previous firm, brings experience spanning the physics, software, and medical device sectors.   6 August 2025
Americas
Settlement ends expectations of SCOTUS petition | Federal Circuit stipulates patents must explicitly claim the active ingredient of a drug to qualify for Orange Book listing | FTC backs Amneal, saying ‘improper listings’ stifle generic competition.   31 July 2025
Americas
Judge said it was unjustified to allow pharma giant’s exclusivity to continue indefinitely | Loss of monopoly over $7.8bn drug set to have marked revenue impact on the company.   22 July 2025
Europe
Non-profit alleges that Humira pricing displaced essential healthcare, violated EU competition law and breached human rights | Court notes ‘social significance’ of case—but this can’t translate into ‘legal standing’.   18 July 2025
Europe
Pharma giant can’t stop generics from unveiling copies of flagship product | Lord Justice Arnold upholds UK findings of lack of inventive step and insufficiency.   17 July 2025
Americas
Janssen filed patent infringement suits in New Jersey and Delaware over proposed copy of blockbuster drug Invega Sustenna | Lawsuits follow appeals court win for J&J in separate action with Teva and Mylan.   15 July 2025
Careers
New hire is deeply involved in the litigation space and has co-founded two software businesses.   11 July 2025

Not finding what you're looking for, please try resetting your applied search and filters,
or try the
full site search.